Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: | Psychiatry/Psychology
Search Medical Condition
Psychosis Clinical Trials
A listing of Psychosis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Found (1000) clinical trials
Study Seeking Patients with Schizophrenia
A phase III study to evaluate weight gain of ALKS3831 compared to olanzapine in adults with schizophrenia
A Randomized, Double-blind, Placebo-controlled, Two-cohort, Parallel Group Study to Evaluate the Efficacy of CAD106 and CNP520 in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease.
Study Description: The purpose of this study is to test whether two investigational drugs called CAD106 and CNP520, administered separately, can slow down the onset and progression of clinical symptoms associated with Alzheimer's disease (AD) in participants at the risk to develop clinical symptoms based on their age and genotype. ...
Alzheimer's Disease
People who may develop Alzheimer's Disease are asked to participate in a research study being conducted by New York University School of Medicine.
A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Study Investigating the Efficacy and Safety of JNJ-54861911 in Subjects Who Are Asymptomatic At Risk for Developing Alzheimer's Dementia
The purpose of this study is to evaluate whether treatment with JNJ-54861911 slows cognitive decline compared with placebo treatment, as measured by a composite cognitive measure, the Preclinical Alzheimer Cognitive Composite (PACC), in amyloid-positive participants who are asymptomatic at risk for developing Alzheimer's dementia. May be compensated for time and ...
A Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of AVP-786 for the treatment of agitation in patients with dementia of the Alzheimer’s type.
The study will evaluate the efficacy, safety, and tolerability of a medication: AVP-786 compared to placebo, for the treatment of agitation in patients with dementia of the Alzheimer’s type. Approximately 325 patients will be enrolled at approximately 50 centers in North America.
Generation 1 Alzheimer’s Risk
This study tests whether two investigational drugs called CAD106 and CNP520, administered separately, can delay and slow the progression of clinical symptoms associated with Alzheimer's Disease in participants at risk of developing clinical symptoms based on their age and genotype. Other Details: https://clinicaltrials.gov/ct2/show/NCT02565511
Daybreak
Evaluate the efficacy of Lanabecestat in mild Alzheimer's Disease dementia Other Details: https://clinicaltrials.gov/ct2/show/study/NCT02783573
A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects with Mild Alzheimer’s Disease
The primary objective is to evaluate the effects of administration of neflamapimod (VX-745) for 24-weeks on immediate and delayed recall aspects of episodic memory, as assessed by the Hopkins Verbal Learning Test – Revised (HVLT-R) in subjects with mild Alzheimer’s disease (AD).
EARLY Trial - A Clinical Trial for Those at Risk of Developing Memory Loss Due to Alzheimer's disease
The purpose of this study is to evaluate whether the investigational medication, JNJ-54861911, slows cognitive decline compared with placebo (inactive treatment) in individuals with generally normal memory and thinking ability but who are at risk for developing Alzheimer's dementia. Study qualification and whether or not a potential study participant is ...
A study to evaluate the safety and efficacy of an oral investigational drug in individuals who are asymptomatic and at-risk for Alzheimer's disease.
The primary objective of this study is to determine whether treatment with an oral investigational drug can slow cognitive decline compared with placebo treatment in individuals who are asymptomatic but at high risk for Alzheimer's disease. Asymptomatic means that the individual is not currently experiencing any symptoms of memory loss ...
